Dr George Chiuchi Huang, MD | |
1709 164th St Se, Mill Creek, WA 98012-8080 | |
(425) 338-7877 | |
Not Available |
Full Name | Dr George Chiuchi Huang |
---|---|
Gender | Male |
Speciality | Plastic Surgery |
Location | 1709 164th St Se, Mill Creek, Washington |
Accepts Medicare Assignments | Does not participate in Medicare Program. He may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1245535012 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208200000X | Plastic Surgery | MD00032946 (Washington) | Primary |
Mailing Address | Practice Location Address |
---|---|
Dr George Chiuchi Huang, MD 1709 164th St Se, Mill Creek, WA 98012-8080 Ph: (425) 338-7877 | Dr George Chiuchi Huang, MD 1709 164th St Se, Mill Creek, WA 98012-8080 Ph: (425) 338-7877 |
News Archive
For many of the millions of patients treated annually in hospitals for upper gastrointestinal (GI) bleeding, there is little value in placing a nasogastric (NG) tube in patients to determine the source of that bleeding or size of a lesion, report investigators in an article published online ahead of print on January 9, 2017 by the Journal of Investigative Medicine.
By furthering scientists' understanding of the molecular mechanisms that separate the minority of successful HIV antibodies from the majority of ineffective antibodies, the work may have implications for future attempts to design an HIV vaccine.
A new study indicates that African Americans with a family history of colorectal cancer are less likely to be screened than African Americans at average risk for the disease. There is also some evidence to indicate that AA with a family history are less likely to be screened than their white counterparts. The study is published in the July 15, 2008 issue of CANCER, a peer-reviewed journal of the American Cancer Society.
Amgen today announced submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration seeking approval for its investigational bispecific T cell engager (BiTE) antibody construct, blinatumomab.
› Verified 6 days ago